ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RCI001

A development code. Also written as “RCI001 Eye Drops 0.25%”, “RCI001 Ophthalmic Solution” and “0.25% RCI001 Ophthalmic Solution”.

Its studies are mostly in Dry Eye Syndromes, led by 2 companies.

Furthest: phase 2, since May 12, 20263 company-led studies, 2 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rudacureits history only21 open or runningphase 2since May 12, 2026May 12, 2026Jun 30, 2028phase 2 · NCT07625124
ORA11 open or runningphase 2since Jun 27, 2025Jun 27, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ORA only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2025First study: phase 2 study in Dry Eye SyndromesFirst studyNCT07068958 · 200 planned

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study ORA leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07068958Dry Eye Syndromes2Not yet recruitingNov 1, 2025200

How it is read

Names in the registry

  • “RCI001 Eye Drops 0.25%”, 1 entry
  • “RCI001 Ophthalmic Solution”, 1 entry
  • “0.25% RCI001 Ophthalmic Solution”, 1 entry

Codes read as this program: RCI001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.